<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MISOPROSTOL - misoprostol tablet </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>Misoprostol <br>Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="boxed_warning"></a><a name="section-1"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">MISOPROSTOL ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE ABORTION, <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">PREMATURE BIRTH</span>, OR <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">BIRTH DEFECTS</span>. <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">UTERINE RUPTURE</span> HAS BEEN REPORTED WHEN MISOPROSTOL WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION BEYOND THE EIGHTH WEEK OF PREGNANCY (see also <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span> and <span class="Bold"><a href="#precautions_labor">LABOR AND DELIVERY</a></span>). MISOPROSTOL SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ULCERS</span> INDUCED BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) (see <span class="Bold"><a href="#contraindications">CONTRAINDICATIONS</a></span>, <span class="Bold"><a href="#warnings">WARNINGS</a></span>, and <span class="Bold"><a href="#precautions">PRECAUTIONS</a></span>).</p>
<p>PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS.</p>
<p>Misoprostol should not be used for reducing the risk of NSAID-induced <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in women of childbearing potential unless the patient is at high risk of complications from <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, misoprostol may be prescribed if the patient</p>
<ul>
<li>has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.</li>
<li>is capable of complying with effective contraceptive measures.</li>
<li>has received both oral and written warnings of the hazards of misoprostol, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.</li>
<li>will begin misoprostol only on the second or third day of the next normal menstrual period.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Misoprostol oral tablets contain either 100 mcg or 200 mcg of misoprostol, a synthetic prostaglandin E<span class="Sub">1</span> analog.</p>
<p>Misoprostol contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by (±):</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83554310-3991-4a9d-92f1-d71ccfd0fb3a&amp;name=misoprostol-01.jpg"></div>
<p>Misoprostol is a water-soluble, viscous liquid.</p>
<p>Inactive ingredients of tablets are hydrogenated castor oil, hypromellose, microcrystalline cellulose, and sodium starch glycolate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical_pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Misoprostol is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs.</p>
<p>In normal volunteers, misoprostol is rapidly absorbed after oral administration with a T<span class="Sub">max</span> of misoprostol acid of 12 ± 3 minutes and a terminal half-life of 20–40 minutes.</p>
<p>There is high variability of plasma levels of misoprostol acid between and within studies but mean values after single doses show a linear relationship with dose over the range of 200–400 mcg. No accumulation of misoprostol acid was noted in multiple dose studies; plasma steady state was achieved within two days.</p>
<p>Maximum plasma concentrations of misoprostol acid are diminished when the dose is taken with food and total availability of misoprostol acid is reduced by use of concomitant antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important.</p>
<a name="ief6e1f8d-109e-45ef-8d6a-04a563922457"></a><table width="75%">
<col align="left" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="First Last">
<th align="left" valign="bottom">Mean ± SD</th>
<th align="center" valign="bottom">C<span class="Sub">max</span>(pg/ml)</th>
<th align="center">AUC(0–4)<br>(pg∙hr/ml)</th>
<th align="center" valign="bottom">T<span class="Sub">max</span>(min)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Comparisons with fasting results statistically significant, p&lt;0.05.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">Fasting</td>
<td align="center">811 ± 317</td>
<td align="center">417 ± 135</td>
<td align="center">14 ± 8</td>
</tr>
<tr>
<td align="left">With Antacid</td>
<td align="center">689 ± 315</td>
<td align="center">349 ± 108<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td align="center">20 ± 14</td>
</tr>
<tr class="Last">
<td align="left">With High Fat Breakfast</td>
<td align="center" valign="top">303 ± 176<a href="#footnote-1" class="Sup">*</a>
</td>
<td align="center" valign="top">373 ± 111</td>
<td align="center" valign="top">64 ± 79<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
</tbody>
</table>
<p>After oral administration of radiolabeled misoprostol, about 80% of detected radioactivity appears in urine. Pharmacokinetic studies in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> showed an approximate doubling of T<span class="Sub">1/2</span>, C<span class="Sub">max</span>, and AUC compared to normals, but no clear correlation between the degree of impairment and AUC. In subjects over 64 years of age, the AUC for misoprostol acid is increased. No routine dosage adjustment is recommended in older patients or patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, but dosage may need to be reduced if the usual dose is not tolerated.</p>
<p>Drug interaction studies between misoprostol and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant.</p>
<p>Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with misoprostol. Misoprostol given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.</p>
<p>The serum protein binding of misoprostol acid is less than 90% and is concentration-independent in the therapeutic range.</p>
<p>After a single oral dose of misoprostol to nursing mothers, misoprostol acid was excreted in breast milk.  The maximum concentration of misoprostol acid in expressed breast milk was achieved within 1 hour after dosing and was 7.6 pg/ml (CV 37%) and 20.9 pg/ml (CV 62%) after single 200 µg and 600 µg misoprostol administration, respectively.  The misoprostol acid concentrations in breast milk declined to &lt; 1 pg/ml at 5 hours post-dose.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-2.2"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Misoprostol has both antisecretory (inhibiting gastric acid secretion) and (in animals) mucosal protective properties. NSAIDs inhibit prostaglandin synthesis, and a deficiency of prostaglandins within the gastric mucosa may lead to diminishing <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and mucus secretion and may contribute to the mucosal damage caused by these agents. Misoprostol can increase <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and mucus production, but in man this has been shown at doses 200 mcg and above that are also antisecretory. It is therefore not possible to tell whether the ability of misoprostol to reduce the risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> is the result of its antisecretory effect, its mucosal protective effect, or both.</p>
<p><span class="Italics">In vitro</span> studies on canine parietal cells using tritiated misoprostol acid as the ligand have led to the identification and characterization of specific prostaglandin receptors. Receptor binding is saturable, reversible, and stereospecific. The sites have a high affinity for misoprostol, for its acid metabolite, and for other E type prostaglandins, but not for F or I prostaglandins and other unrelated compounds, such as histamine or cimetidine. Receptor-site affinity for misoprostol correlates well with an indirect index of antisecretory activity. It is likely that these specific receptors allow misoprostol taken with food to be effective topically, despite the lower serum concentrations attained.</p>
<p>Misoprostol produces a moderate decrease in pepsin concentration during basal conditions, but not during histamine stimulation. It has no significant effect on fasting or postprandial gastrin nor on intrinsic factor output.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3"></a><p></p>
<h2>Effects on gastric acid secretion</h2>
<p class="First">Misoprostol, over the range of 50–200 mcg, inhibits basal and nocturnal gastric acid secretion, and acid secretion in response to a variety of stimuli, including meals, histamine, pentagastrin, and coffee. Activity is apparent 30 minutes after oral administration and persists for at least 3 hours. In general, the effects of 50 mcg were modest and shorter lived, and only the 200-mcg dose had substantial effects on nocturnal secretion or on histamine and meal-stimulated secretion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>Uterine effects</h2>
<p class="First">Misoprostol has been shown to produce uterine contractions that may endanger pregnancy. (See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.5"></a><p></p>
<h2>Other pharmacologic effects</h2>
<p class="First">Misoprostol does not produce clinically significant effects on serum levels of prolactin, gonadotropins, thyroid-stimulating hormone, growth hormone, thyroxine, cortisol, gastrointestinal hormones (somatostatin, gastrin, vasoactive intestinal polypeptide, and motilin), creatinine, or uric acid. Gastric emptying, immunologic competence, platelet aggregation, pulmonary function, or the cardiovascular system are not modified by recommended doses of misoprostol.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="clinical_pharmacology_clinical"></a><a name="section-2.6"></a><p></p>
<h2>Clinical studies</h2>
<p class="First">In a series of small short-term (about 1 week) placebo-controlled studies in healthy human volunteers, doses of misoprostol were evaluated for their ability to reduce the risk of NSAID-induced mucosal injury. Studies of 200 mcg q.i.d. of misoprostol with tolmetin and naproxen, and of 100 and 200 mcg q.i.d. with ibuprofen, all showed reduction of the rate of significant endoscopic injury from about 70–75% on placebo to 10–30% on misoprostol. Doses of 25–200 mcg q.i.d. reduced aspirin-induced mucosal injury and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.7"></a><p></p>
<h2>Reducing the risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> caused by nonsteroidal anti-inflammatory drugs (NSAIDs)</h2>
<p class="First">Two 12-week, randomized, double-blind trials in osteoarthritic patients who had <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> but no <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> on endoscopy while taking an NSAID compared the ability of 200 mcg of misoprostol, 100 mcg of misoprostol, and placebo to reduce the risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span> (GU) formation. Patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. The 200-mcg dose caused a marked, statistically significant reduction in <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in both studies. The lower dose was somewhat less effective, with a significant result in only one of the studies.</p>
<a name="i6ca7494c-5b5d-43a0-879c-74dbd61c5cad"></a><table width="100%">
<caption><span>Reduction of Risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">Gastric Ulcers</span> Induced by Ibuprofen, Piroxicam, or Naproxen [No. of patients with <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>(s) (%)]</span></caption>
<col align="left" width="28%">
<col align="center" width="18%">
<col align="center" width="18%">
<col align="center" width="18%">
<col align="center" width="18%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="3">Therapy Duration</th>
<th align="center"></th>
</tr>
<tr class="Last">
<th align="left">Therapy</th>
<th class="Toprule" align="center">4 weeks</th>
<th class="Toprule" align="center">8 weeks</th>
<th class="Toprule" align="center">12 weeks</th>
<th align="center"></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Statistically significantly different from placebo at the 5% level.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Combined data from Study No. 1 and Study No. 2.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5"><span class="Italics">Study No. 1</span></td></tr>
<tr>
<td align="left">Misoprostol<br>  200 mcg<br>  q.i.d. (n=74)</td>
<td align="center">1 (1.4)</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1 (1.4)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Misoprostol<br>  100 mcg<br>  q.i.d. (n=77)</td>
<td align="center">3 (3.9)</td>
<td align="center">1 (1.3)</td>
<td align="center">1 (1.3)</td>
<td align="center">5 (6.5)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td class="Botrule" align="left">Placebo (n=76)</td>
<td class="Botrule" align="center">11 (14.5)</td>
<td class="Botrule" align="center">4 (5.3)</td>
<td class="Botrule" align="center">4 (5.3)</td>
<td class="Botrule" align="center">19 (25.0)</td>
</tr>
<tr><td align="left" colspan="5"><span class="Italics">Study No. 2</span></td></tr>
<tr>
<td align="left">Misoprostol<br>  200 mcg<br>  q.i.d. (n=65)</td>
<td align="center">1 (1.5)</td>
<td align="center">1 (1.5)</td>
<td align="center">0</td>
<td align="center">2 (3.1)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Misoprostol<br>  100 mcg<br>  q.i.d. (n=66)</td>
<td align="center">2 (3.0)</td>
<td align="center">2 (3.0)</td>
<td align="center">1 (1.5)</td>
<td align="center">5 (7.6)</td>
</tr>
<tr>
<td class="Botrule" align="left">Placebo (n=62)</td>
<td class="Botrule" align="center">6 (9.7)</td>
<td class="Botrule" align="center">2 (3.2)</td>
<td class="Botrule" align="center">3 (4.8)</td>
<td class="Botrule" align="center">11 (17.7)</td>
</tr>
<tr><td align="left" colspan="5">
<span class="Italics">Studies No. 1 &amp; No. 2</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a>
</td></tr>
<tr>
<td align="left">Misoprostol<br>  200 mcg<br>  q.i.d. (n=139)</td>
<td align="center">2 (1.4)</td>
<td align="center">1 (0.7)</td>
<td align="center">0</td>
<td align="center">3 (2.2)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left">Misoprostol<br>  100 mcg<br>  q.i.d. (n=143)</td>
<td align="center">5 (3.5)</td>
<td align="center">3 (2.1)</td>
<td align="center">2 (1.4)</td>
<td align="center">10 (7.0)<a href="#footnote-2" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left">Placebo (n=138)</td>
<td class="Botrule" align="center">17 (12.3)</td>
<td class="Botrule" align="center">6 (4.3)</td>
<td class="Botrule" align="center">7 (5.1)</td>
<td class="Botrule" align="center">30 (21.7)</td>
</tr>
</tbody>
</table>
<p>In these trials there were no significant differences between misoprostol and placebo in relief of day or night <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. No effect of misoprostol in reducing the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> was demonstrated, but relatively few duodenal lesions were seen.</p>
<p>In another clinical trial, 239 patients receiving aspirin 650–1300 mg q.i.d. for <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> who had endoscopic evidence of duodenal and/or gastric <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> were randomized to misoprostol 200 mcg q.i.d. or placebo for 8 weeks while continuing to receive aspirin. The study evaluated the possible interference of misoprostol on the efficacy of aspirin in these patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> by analyzing joint <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, physician's clinical assessment, patient's assessment, change in ARA classification, change in handgrip strength, change in duration of morning <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, patient's assessment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at rest, movement, interference with daily activity, and ESR. Misoprostol did not interfere with the efficacy of aspirin in these patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Misoprostol is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in patients at high risk of complications from <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>, eg, the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span>. Misoprostol has not been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> in controlled studies of 3 months' duration. It had no effect, compared to placebo, on <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span> or <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> associated with NSAID use.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span></p>
<p><span class="Bold">Misoprostol should not be taken by pregnant women to reduce the risk of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> induced by nonsteroidal anti-inflammatory drugs (NSAIDs).</span></p>
<p>Misoprostol should not be taken by anyone with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to prostaglandins.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Caution should be employed when administering misoprostol to patients with pre-existing cardiovascular disease.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.1"></a><p></p>
<h2>Information for patients</h2>
<p class="First">Women of childbearing potential using misoprostol to decrease the risk of NSAID-induced <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> should be told that they must not be pregnant when misoprostol therapy is initiated, and that they must use an effective contraception method while taking misoprostol.</p>
<p>See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span></p>
<p>Misoprostol is intended for administration along with nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, to decrease the chance of developing an NSAID-induced <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcer</span>.</p>
<p>Misoprostol should be taken only according to the directions given by a physician.</p>
<p>If the patient has questions about or problems with misoprostol, the physician should be contacted promptly.</p>
<p><span class="Bold">THE PATIENT SHOULD NOT GIVE MISOPROSTOL TO ANYONE ELSE.</span> Misoprostol has been prescribed for the patient's specific condition, may not be the correct treatment for another person, and may be dangerous to the other person if she were to become pregnant.</p>
<p>The misoprostol package the patient receives from the pharmacist will include a leaflet containing patient information. The patient should read the leaflet before taking misoprostol and each time the prescription is renewed because the leaflet may have been revised.</p>
<p>Keep misoprostol out of the reach of children.</p>
<p><span class="Bold">SPECIAL NOTE FOR WOMEN: Misoprostol may cause abortion (sometimes incomplete), <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span>, or <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> if given to pregnant women.</span></p>
<p>Misoprostol is available only as a unit-of-use package that includes a leaflet containing patient information. See <span class="Italics"><a href="#patient_information">Patient Information</a></span> at the end of this labeling.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.2"></a><p></p>
<h2>Drug interactions</h2>
<p class="First">See <span class="Italics"><a href="#clinical_pharmacology">Clinical Pharmacology</a></span>. Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>. Misoprostol does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Misoprostol has no clinically significant effect on the kinetics of diclofenac or ibuprofen.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-6.3"></a><p></p>
<h2>Animal toxicology</h2>
<p class="First">A reversible increase in the number of normal surface gastric epithelial cells occurred in the dog, rat, and mouse. No such increase has been observed in humans administered misoprostol for up to 1 year.</p>
<p>An apparent response of the female mouse to misoprostol in long-term studies at 100 to 1000 times the human dose was <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">hyperostosis</span>, mainly of the medulla of sternebrae. <span class="product-label-link" type="condition" conceptid="72715" conceptname="Exostosis">Hyperostosis</span> did not occur in long-term studies in the dog and rat and has not been seen in humans treated with misoprostol.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility</h2>
<p class="First">There was no evidence of an effect of misoprostol on tumor occurrence or incidence in rats receiving daily doses up to 150 times the human dose for 24 months. Similarly, there was no effect of misoprostol on tumor occurrence or incidence in mice receiving daily doses up to 1000 times the human dose for 21 months. The mutagenic potential of misoprostol was tested in several <span class="Italics">in vitro</span> assays, all of which were negative.</p>
<p>Misoprostol, when administered to breeding male and female rats at doses 6.25 times to 625 times the maximum recommended human therapeutic dose, produced dose-related pre- and post-implantation losses and a significant decrease in the number of live pups born at the highest dose. These findings suggest the possibility of a general adverse effect on fertility in males and females.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy: Pregnancy Category X</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.5.1"></a><p></p>
<h3>Teratogenic effects</h3>
<p class="First">See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span> Congenital anomalies sometimes associated with <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> have been reported subsequent to the unsuccessful use of misoprostol as an abortifacient, but the drug's teratogenic mechanism has not been demonstrated. Several reports in the literature associate the use of misoprostol during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span>.</p>
<p>Misoprostol is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the human dose, respectively.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-6.5.2"></a><p></p>
<h3>Nonteratogenic effects</h3>
<p class="First">See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span> Misoprostol may endanger pregnancy (may cause abortion) and thereby cause harm to the fetus when administered to a pregnant woman. Misoprostol may produce uterine contractions, <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>, and expulsion of the products of conception. Abortions caused by misoprostol may be incomplete. If a woman is or becomes pregnant while taking this drug to reduce the risk of NSAID-induced <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, the drug should be discontinued and the patient apprised of the potential hazard to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="precautions_labor"></a><a name="section-6.6"></a><p></p>
<h2>Labor and delivery</h2>
<p class="First">Misoprostol can induce or augment uterine contractions. Vaginal administration of misoprostol, outside of its approved indication, has been used as a cervical ripening agent, for the induction of labor and for treatment of serious <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span> in the presence of <span class="product-label-link" type="condition" conceptid="4127206" conceptname="Uterus relaxed">uterine atony</span>. A major adverse effect of the obstetrical use of misoprostol is the hyperstimulation of the uterus which may progress to uterine <span class="product-label-link" type="condition" conceptid="380534" conceptname="Tetany">tetany</span> with marked impairment of uteroplacental blood flow, <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span> (requiring surgical repair, hysterectomy, and/or salpingo-oophorectomy), or <span class="product-label-link" type="condition" conceptid="435616" conceptname="Amniotic fluid embolism">amniotic fluid embolism</span>. <span class="product-label-link" type="condition" conceptid="4147829" conceptname="Pain in pelvis">Pelvic pain</span>, <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span>, severe genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="314749" conceptname="Fetal bradycardia">fetal bradycardia</span>, and fetal and maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported.</p>
<p>There may be an increased risk of uterine tachysystole, <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span>, meconium passage, meconium staining of amniotic fluid, and Cesarean delivery due to <span class="product-label-link" type="condition" conceptid="192698" conceptname="Hypertonic uterine dysfunction">uterine hyperstimulation</span> with the use of higher doses of misoprostol, including the manufactured 100 mcg tablet. The risk of <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span> increases with advancing gestational ages and with prior uterine surgery, including Cesarean delivery. Grand multiparity also appears to be a risk factor for <span class="product-label-link" type="condition" conceptid="195328" conceptname="Rupture of uterus before onset of labor">uterine rupture</span>.</p>
<p>The effect of misoprostol on later growth, development, and functional maturation of the child when misoprostol is used for cervical ripening or induction of labor has not been established. Information on misoprostol's effect on the need for forceps delivery or other intervention is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.7"></a><p></p>
<h2>Nursing mothers</h2>
<p class="First">Misoprostol is rapidly metabolized in the mother to misoprostol acid, which is biologically active and is excreted in breast milk. There are no published reports of adverse effects of misoprostol in breast-feeding infants of mothers taking misoprostol. Caution should be exercised when misoprostol is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.8"></a><p></p>
<h2>Pediatric use</h2>
<p class="First">Safety and effectiveness of misoprostol in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following have been reported as adverse events in subjects receiving misoprostol:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">In subjects receiving misoprostol 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> at 800 mcg in controlled trials in patients on NSAIDs ranged from 14–40% and in all studies (over 5,000 patients) averaged 13%. <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> occurred in 13–20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was dose-related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of misoprostol (2% of the patients). Rare instances of profound <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> leading to severe <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> have been reported. Patients with an underlying condition such as <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>, or those in whom <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, were it to occur, would be dangerous, should be monitored carefully if misoprostol is prescribed. The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> can be minimized by administering after meals and at bedtime, and by avoiding coadministration of misoprostol with magnesium-containing antacids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Gynecological</h2>
<p class="First">Women who received misoprostol during clinical trials reported the following gynecological disorders: spotting (0.7%), <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> (0.6%), <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">hypermenorrhea</span> (0.5%), <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span> (0.3%) and <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> (0.1%). Postmenopausal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> may be related to misoprostol administration. If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology. (See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>Elderly</h2>
<p class="First">There were no significant differences in the safety profile of misoprostol in approximately 500 <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> patients who were 65 years of age or older compared with younger patients.</p>
<p>Additional adverse events which were reported are categorized as follows:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Incidence greater than 1%</h2>
<p class="First">In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving misoprostol and may be causally related to the drug: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3.2%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (2.9%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.4%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (2.0%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1.3%), and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (1.1%). However, there were no significant differences between the incidences of these events for misoprostol and placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Causal relationship unknown</h2>
<p class="First">The following adverse events were infrequently reported. Causal relationships between misoprostol and these events have not been established but cannot be excluded:</p>
<p><span class="Italics">Body as a whole:</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">aches</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pains</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, weight changes.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>.</p>
<p><span class="Italics">Special senses:</span> abnormal taste, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span>.</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, increased cardiac enzymes, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (some fatal), <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> (e.g., <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, and CVA).</p>
<p><span class="Italics">Gastrointestinal:</span> GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, GI <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>/<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, abnormal hepatobiliary function, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, reflux, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, amylase increase.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span></p>
<p><span class="Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, increased nitrogen, increased alkaline phosphatase.</p>
<p><span class="Italics">Genitourinary:</span> <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p><span class="Italics">Nervous system/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> increase, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiffness</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>.</p>
<p><span class="Italics">Blood/Coagulation:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, abnormal differential, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4013526" conceptname="ESR raised">ESR increased</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The toxic dose of misoprostol in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal discomfort</span> being reported. In animals, the acute toxic effects are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gastrointestinal lesions, focal cardiac <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span>, respiratory difficulties, and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the central nervous system. Clinical signs that may indicate an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are sedation, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. Symptoms should be treated with supportive therapy.</p>
<p>It is not known if misoprostol acid is dialyzable. However, because misoprostol is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended adult oral dose of misoprostol for reducing the risk of NSAID-induced <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span> is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used. (See <span class="Italics"><a href="#clinical_pharmacology_clinical">Clinical Pharmacology: Clinical studies</a></span>.) Misoprostol should be taken for the duration of NSAID therapy as prescribed by the physician. Misoprostol should be taken with a meal, and the last dose of the day should be at bedtime.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></h2>
<p class="First">Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See <span class="Italics"><a href="#clinical_pharmacology">Clinical Pharmacology</a></span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Misoprostol 100-mcg tablets are white, round, with G and 5007 debossed on one side; supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>            <span class="Bold Underline">Size</span><br>59762-5007-1            unit-of-use bottle of 60<br>59762-5007-2            unit-of-use bottle of 120</p>
<p>Misoprostol 200-mcg tablets are white, hexagonal, with G debossed above and 5008 debossed below the line on one side; supplied as:</p>
<p><span class="Bold Underline">NDC Number</span>            <span class="Bold Underline">Size</span><br>59762-5008-1            unit-of-use bottle of 60<br>59762-5008-2            unit-of-use bottle of 100</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2></h2>
<p class="First">Store at or below 25°C (77°F), in a dry area.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<h1>PATIENT INFORMATION</h1>
<p class="First">Read this leaflet before taking misoprostol and each time your prescription is renewed, because the leaflet may be changed.</p>
<p>Misoprostol is being prescribed by your doctor to decrease the chance of getting <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span> related to the <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication that you take.</p>
<p>Do not take misoprostol to reduce the risk of NSAID-induced <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> if you are pregnant. (See boxed <span class="Bold"><a href="#boxed_warning">WARNINGS</a></span>.) Misoprostol can cause abortion (sometimes incomplete which could lead to dangerous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and require hospitalization and surgery), <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">premature birth</span>, or <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. It is also important to avoid pregnancy while taking this medication and for at least one month or through one menstrual cycle after you stop taking it. Misoprostol has been reported to cause the uterus to rupture (tear) when given after the eighth week of pregnancy. Rupture (tearing) of the uterus can result in severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, hysterectomy, and/or maternal or <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>.</p>
<p>If you become pregnant during misoprostol therapy, stop taking misoprostol and contact your physician immediately. Remember that even if you are on a means of birth control it is still possible to become pregnant. Should this occur, stop taking misoprostol and contact your physician immediately.</p>
<p>Misoprostol may cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, abdominal cramping, and/or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> in some people. In most cases these problems develop during the first few weeks of therapy and stop after about a week. You can minimize possible <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> by making sure you take misoprostol with food.</p>
<p>Because these side effects are usually mild to moderate and usually go away in a matter of days, most patients can continue to take misoprostol. If you have prolonged difficulty (more than 8 days), or if you have severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, cramping and/or <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, call your doctor.</p>
<p>Take misoprostol only according to the directions given by your physician.</p>
<p>Do not give misoprostol to anyone else. It has been prescribed for your specific condition, may not be the correct treatment for another person, and would be dangerous if the other person were pregnant.</p>
<p>This information sheet does not cover all possible side effects of misoprostol. This patient information leaflet does not address the side effects of your <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medication. See your doctor if you have questions.</p>
<p>Keep out of reach of children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83554310-3991-4a9d-92f1-d71ccfd0fb3a&amp;name=misoprostol-02.jpg"></p>
<p>LAB-0171-4.0<br>September 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mcg tablet bottle</h1>
<p class="First"><span class="Bold">NDC</span> 59762-5008-1<br>60 Tablets</p>
<p>GREENSTONE<span class="Sup">®</span> BRAND</p>
<p><span class="Bold">misoprostol<br>tablets</span></p>
<p><span class="Bold">200 mcg</span></p>
<p><span class="Bold">Usual Adult Dosage:</span><br>See accompanying literature.</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="55289640 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=83554310-3991-4a9d-92f1-d71ccfd0fb3a&amp;name=55289640.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MISOPROSTOL 		
					</strong><br><span class="contentTableReg">misoprostol tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-640(NDC:59762-5007)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>misoprostol</strong> (misoprostol) </td>
<td class="formItem">misoprostol</td>
<td class="formItem">100 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrogenated castor oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">G;5007</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-640-02</td>
<td class="formItem">2  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55289-640-04</td>
<td class="formItem">4  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:55289-640-06</td>
<td class="formItem">6  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:55289-640-08</td>
<td class="formItem">8  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:55289-640-13</td>
<td class="formItem">13  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019268</td>
<td class="formItem">12/27/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>65daea3d-0608-4d18-8066-b813d325f474</div>
<div>Set id: 83554310-3991-4a9d-92f1-d71ccfd0fb3a</div>
<div>Version: 3</div>
<div>Effective Time: 20091015</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
